Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, EnBio Holdings's Enterprise Value is 円12,605 Mil.
EnBio Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,094 Mil. Therefore, EnBio Holdings's EV-to-EBIT ratio for today is 11.52.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, EnBio Holdings's Enterprise Value is 円12,605 Mil.
EnBio Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,637 Mil. Therefore, EnBio Holdings's EV-to-EBITDA ratio for today is 7.70.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, EnBio Holdings's Enterprise Value is 円12,605 Mil.
EnBio Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円12,630 Mil. Therefore, EnBio Holdings's EV-to-Revenue ratio for today is 1.00.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, EnBio Holdings's Enterprise Value is 円12,605 Mil.
EnBio Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円0 Mil. Therefore, EnBio Holdings's EV-to-FCF ratio for today is .
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
EnBio Holdings (TSE:6092) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
EnBio Holdings's current Enterprise Value is 円12,605 Mil.
EnBio Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,094 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
EnBio Holdings's current Enterprise Value is 円12,605 Mil.
EnBio Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,637 Mil.
EnBio Holdings's current Enterprise Value is 円12,605 Mil.
EnBio Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円12,630 Mil.
EnBio Holdings's current Enterprise Value is 円12,605 Mil.
EnBio Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
EnBio Holdings's current Enterprise Value is 円12,605 Mil.
EnBio Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EnBio Holdings Enterprise Value Related Terms
EnBio Holdings Enterprise Value Historical Data
* Premium members only.
The historical data trend for EnBio Holdings's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6092 vs CTAS, CPRT, ULS: Enterprise Value Comparison
For the Specialty Business Services subindustry, EnBio Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EnBio Holdings Enterprise Value vs Business Services Industry
For the Business Services industry and Industrials sector, EnBio Holdings's Enterprise Value distribution charts can be found below:
* The bar in red indicates where EnBio Holdings's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EnBio Holdings's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EnBio Holdings (TSE:6092) has a Enterprise Value of 円12,605 Mil as of Jul. 17, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on EnBio Holdings and its competitors.
Is EnBio Holdings' Enterprise Value too high?
EnBio Holdings' current Enterprise Value is 円12,605 Mil. Overall, EnBio Holdings has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does EnBio Holdings' Enterprise Value compare to CTAS and CPRT?
EnBio Holdings' Enterprise Value of 円12,605 Mil can be compared against companies in the Business Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Business Services company?
A good Enterprise Value depends on the Business Services industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on EnBio Holdings and its competitors. EnBio Holdings's current Enterprise Value is 円12,605 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EnBio Holdings stock overvalued right now?
Based on GuruFocus' analysis, EnBio Holdings (TSE:6092) is currently considered Fairly Valued. The stock's GF Value™ is 円799.37, compared to a current price of 円728.00 — trading 8.9% below its estimated fair value. The current Enterprise Value is 円12,605 Mil. EnBio Holdings' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For EnBio Holdings (TSE:6092), the current Enterprise Value is 円12,605 Mil as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EnBio Holdings (TSE:6092) Overvalued in 2026?
Based on GuruFocus' analysis, EnBio Holdings stock appears to be undervalued.
The current stock price of 円728.00 is trading 8.9% below its estimated GF Value™ of 円799.37.
GuruFocus considers EnBio Holdings to be Fairly Valued.
Key valuation signals for TSE:6092:
Enterprise Value: 円12,605 Mil
GF Value™: 円799.37 vs. price of 円728.00 (8.9% below fair value)
No single metric tells the full story. See the TSE:6092 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EnBio Holdings Inc is a Japanese company engaged in environmental solution business, tools and chemicals business, and brownfield revitalization business. The environmental business involves investigation, remediation and risk management consulting of contaminated soil and groundwater; Tools and chemicals business involves sales of chemicals used for environmental work such as site investigation and remediation; and brownfield revitalization business which involves purchasing and regeneration of brownfields. The objective of the company is solving soil and groundwater contamination issues.
58GF Score
Get the complete analysis for TSE:6092
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6092 has been successfully added to your 
